Epigenetic plus cytokine therapy evades checkpoint blockade resistance by potentiating cytotoxic CD8+ T cells with stem-immunity clusters [ATAC-seq]
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE279355 | GEO | 2026/08/31
REPOSITORIES: GEO
Similar Datasets
Project description:HPV-associated malignancies continue to present a major health concern despite the development of prophylactic vaccines. Standard therapies offer limited benefit to patients with advanced stage disease. Despite improved outcomes with PD-1 targeted therapies, treatment resistance and modest response rates highlight a significant unmet need to develop novel therapies for these patients. PDS0101 (designated HPV vaccine) is a liposomal nanoparticle HPV16-specific therapeutic vaccine that has been shown to generate strong HPV-specific responses in pre-clinical and clinical studies. Here we assess the efficacy of this HPV vaccine in combination with the tumor-targeting immunocytokine NHS-IL12 (PDS01ADC), plus either aPD-1 or the class I histone deacetylase (HDAC) inhibitor Entinostat. Mice bearing HPV16+, aPD-1 refractory TC-1 and mEER tumors were treated with HPV vaccine, NHS-IL12, and either aPD-1 or Entinostat to determine anti-tumor efficacy and survival benefits. A comprehensive analysis of the tumor microenvironment was performed using flow cytometry, multiplex immunofluorescence, chemokine and cytokine assessment, and scRNAseq with TCR enrichment. Combination of HPV vaccine and NHS-IL12 with either Entinostat or aPD-1 yields significant anti-tumor activity and prolonged survival in aPD-1 refractory models of HPV16+ cancer, with superior activity employing Entinostat versus aPD-1 combination. Entinostat triple therapy increased overall and HPV16-specific tumor CD8+ T cell infiltration with heightened cytotoxicity. TCR sequencing revealed a CD8+ T cell clone unique to vaccine-treated cohorts, which displayed an enriched cytotoxic transcriptional profile with triple therapy. These effects were parallelled by strong differentiation of tumor-associated macrophages (TAMs) towards proinflammatory, anti-tumor M1-like cell states. Single-cell transcriptomic analysis indicated all three agents were required for highest modulation of both CD8+ T cells and TAMs conducive to tumor control. A biomarker signature reflecting the pre-clinical findings was found to be associated with improved survival in patients with HPV-associated malignancies. Together, these findings provide a rationale for the combination of HPV vaccine, NHS-IL12, and Entinostat in the clinical setting for patients with HPV16-associated malignancies.
2025-05-07 | GSE295238 | GEO
Project description:Microsatellite-stable (MSS) colorectal cancers (CRC) display inherent insensitivity to immune checkpoint blockade, and the pivotal mechanisms responsible for this immunotherapeutic resistance have not been fully clarified. Here, we demonstrate that MSS CRC elicit CD8⁺ T cell senescence to mediate immune evasion, which distinguishes them from microsatellite-instable (MSI) CRC. We further identify SEMA3A, a secreted protein markedly upregulated in MSS CRC, as a crucial mediator that directly drives CD8⁺ T cell senescence. Mechanistically, SEMA3A engages neuropilin-1 (NRP1) to hijack JAK1 signaling, which blunts cytokine-triggered STAT3 phosphorylation and ultimately reduces TCF1 expression. At the molecular level, TCF1 directly binds to and transcriptionally represses senescence-associated genes. The loss of TCF1 in CD8⁺ T cells infiltrating MSS CRC tumors abolishes this transcriptional repression, thereby inducing CD8⁺ T cell senescence and conferring refractoriness to PD-L1 blockade. In syngeneic murine models of MSS CRC, dual neutralization of SEMA3A and PD-L1 restores TCF1 expression, rescues CD8⁺ T cells from senescence, and significantly improves immunotherapy efficacy. Clinical data corroborate that SEMA3A expression is positively correlated with CD8⁺ T cell senescence and serves as a reliable prognostic biomarker for inferior immunotherapy responses in patients with MSS CRC. Collectively, this study delineates a SEMA3A/NRP1-JAK1-STAT3-TCF1 signaling axis that governs CD8⁺ T cell senescence and tumor immune evasion in MSS CRCs, validating SEMA3A as a promising predictive biomarker and druggable therapeutic target for this immunotherapy-refractory MSS CRC.
2026-08-17 | GSE343811 | GEO
Project description:Microsatellite-stable (MSS) colorectal cancers (CRC) display inherent insensitivity to immune checkpoint blockade, and the pivotal mechanisms responsible for this immunotherapeutic resistance have not been fully clarified. Here, we demonstrate that MSS CRC elicit CD8⁺ T cell senescence to mediate immune evasion, which distinguishes them from microsatellite-instable (MSI) CRC. We further identify SEMA3A, a secreted protein markedly upregulated in MSS CRC, as a crucial mediator that directly drives CD8⁺ T cell senescence. Mechanistically, SEMA3A engages neuropilin-1 (NRP1) to hijack JAK1 signaling, which blunts cytokine-triggered STAT3 phosphorylation and ultimately reduces TCF1 expression. At the molecular level, TCF1 directly binds to and transcriptionally represses senescence-associated genes. The loss of TCF1 in CD8⁺ T cells infiltrating MSS CRC tumors abolishes this transcriptional repression, thereby inducing CD8⁺ T cell senescence and conferring refractoriness to PD-L1 blockade. In syngeneic murine models of MSS CRC, dual neutralization of SEMA3A and PD-L1 restores TCF1 expression, rescues CD8⁺ T cells from senescence, and significantly improves immunotherapy efficacy. Clinical data corroborate that SEMA3A expression is positively correlated with CD8⁺ T cell senescence and serves as a reliable prognostic biomarker for inferior immunotherapy responses in patients with MSS CRC. Collectively, this study delineates a SEMA3A/NRP1-JAK1-STAT3-TCF1 signaling axis that governs CD8⁺ T cell senescence and tumor immune evasion in MSS CRCs, validating SEMA3A as a promising predictive biomarker and druggable therapeutic target for this immunotherapy-refractory MSS CRC.
2026-08-17 | GSE343928 | GEO
Project description:The master transcriptional regulator T cell factor 1 (TCF1) is required for the anti-tumor functions of memory and stem-like CD8+ T cells. However, how TCF1 partners with other transcription factors to orchestrate the gene activation program critical for anti-tumor immunity remains poorly understood. Here we show that negative elongation factor B (NELFB), an RNA polymerase II pausing factor, cooperates with TCF1 in T cell responses to cancer. Genetic ablation of mouse Nelfb in mature T lymphocytes severely impaired anti-tumor immunity responding to both primary tumor challenge and tumor antigen-mediated vaccination. NELFB depletion resulted in more exhausted, and reduced memory, T cell populations, whereas its ectopic expression boosted host anti-tumor immunity and efficacy of chimeric antigen receptor (CAR) T-cell immunotherapy. Mechanistically, NELFB is physically associated with TCF1 and recruited preferentially to TCF1-enriched transcriptional enhancers and promoters in CD8+ T cells. Nelfb ablation significantly restricted chromatin accessibility to these TCF1-associated loci. Thus, NELFB is a previously unrecognized functional partner of TCF1 that potentiates the chromatin openness of TCF1-targeting regulatory elements. Our findings also suggest that augmenting NELFB expression in CD8+ T cells may improve therapeutic outcomes of anti-cancer CAR-T immunotherapies.
2022-03-19 | GSE182862 | GEO
Project description:RNA-sequencing analyses were performed in CD8+ T cells sorted from MC38 tumors of WT and Lypd6b−/− mice， To investigate the effects of Lypd6b gene knockout on CD8+ T cells in the colon cancer tumor microenvironment. Abstract Lypd6b is a newly discovered molecule associated with neuromodulation. However, the effects of Lypd6b on the tumor microenvironment and its impact on CD8+ T cell-mediated antitumor immunity remain unknown. Here, we observe that Lypd6b expression is increased significantly in colorectal cancer (CRC) tumor tissues compared to normal tissues. Lypd6b is mainly expressed in CD8+ T cells in tumor tissues. Lypd6b knockout (Lypd6b−/−) mice are resistant to AOM/DSS-induced tumorigenesis. Furthermore, global deficiency or CD8+ cell deficiency of Lypd6b (CD8Lypd6b−/−) inhibits MC38 or CMT-93 tumor growth and promotes the infiltration of CD8+ T cells. Mechanistically, Lypd6b deficiency promotes activation and function of CD8+ T cells in anti-tumor response with increased glycolysis and reduced oxidative phosphorylation (OXPHOS) in a PI3K/mTOR/LDHA pathway-dependent manner. Notably, Lypd6b deficient CD8+ T cells have a more potent antitumor effect when combined with anti-PD1 antibody. Thus, Lypd6b as a negative regulator for T cell immunity promotes CRC development, providing a molecular target with therapeutic potential in CRC.
2025-12-11 | E-MTAB-16060 | biostudies-arrayexpress
Project description:PD-1 blockade is important in treating progressive colorectal cancer (CRC). However, some patients with CRC have a poor or no response to immunotherapy. An important reason for this problem is the exhaustion of CD8+ T cells in the tumor microenvironment. Acetylcysteine (NAC) can reduce CD8+ T cell exhaustion in vitro and induce their differentiation into long-lasting phenotypes, thus enhancing the anti-tumor effect of adoptive T cell transfer. However, whether NAC can be combined with PD-1 blockade in CRC treatment and how NAC regulates CD8+ T cell differentiation remains unclear. We constructed a mouse CRC model to study the effect of NAC on tumors. The effect of NAC on CD8+ T cell differentiation and its potential mechanism were explored by cell flow assay and other studies in vitro and ex vivo. We demonstrated that NAC synergized PD-1 antibodies to inhibit CRC progression in a mouse CRC model, mediated by CD8+ T cells. NAC induces TCF1+PD1+CD8+ T cell differentiation and reduces the formation of exhausted T cells (Tex). Moreover, NAC enhanced the expression of Glut4 in CD8+ T cells, promoting the differentiation of TCF1+PD1+CD8+ T cells. Our study provides a novel idea for immunotherapy of clinically progressive CRC and suggests that Glut4 may be a new immunometabolic molecular target for regulating CD8+ T cell differentiation.
2024-05-23 | GSE252358 | GEO
Project description:Cancer immunotherapies boost antitumor immunity and improve the survival of cancer patients. V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an immune 20 checkpoint target but presents elusive signaling mechanisms. We report a novel VISTA binding partner, Leucine-Rich Repeats and Immunoglobulin Like Domains 1 (LRIG1), which acts as an inhibitory receptor by engaging VISTA and suppressing T cell receptor signaling pathways. Mice with T cell-specific LRIG1 deletion developed superior antitumor T cell responses. Mechanistically, LRIG1-deficient tumor-specific CD8+ cytotoxic T cells (CTLs) exhibited longer 25 persistence due to improved expansion and survival and greater effector function. Sustained tumor control was also associated with a reduction of quiescent CTLs (TCF1+ CD62Lhi PD-1low) and a reciprocal increase in progenitor and memory-like CTLs (TCF1+ PD-1+). In human melanoma, an elevated LRIG1 expression on tumor-infiltrating CD8+ CTLs correlated with resistance to immunotherapies. Taken together, these results delineate the role of LRIG1 as an inhibitory 30 immune checkpoint receptor and propose a rationale for targeting the VISTA/LRIG1 axis for cancer immunotherapy.
2024-10-17 | PXD050084 | Pride
Project description:Stem-like CD8 + T cells are regulated by the transcription factor TCF1 and are key players in the response to immune checkpoint blockade (ICB). However, recent findings indicate that reliance on TCF1 + CD8 + stem-like T cells for ICB efficacy may not be equal across patients or tumor contexts. Here, we uncovered that TCF1-deficient CD8 + T cells showed defective priming in the tumor-draining lymph node of mice bearing poorly immunogenic tumors and that TCF1 regulates optimal T cell responsiveness to low TCR triggering. Importantly, we found that TCF1 was dispensable for therapy response in settings where ICB expanded intra-tumoral transitory effector-like cells. Conversely, TCF1 was required for ICB response in tumors that failed to expand cytotoxic effectors and accumulated Tox + dysfunctional T cells. In the absence of TCF1, dysfunctional T cells became destabilized and shared features with CD8 + T cells found in patients that fail ICB. Our study highlights a role for TCF1 in the early stages of the anti-tumor CD8 + T cell response with important implications for guiding optimal therapeutic interventions in cancers with low frequency of TCF1 + CD8 + T cells and low neoantigen levels.
2023-08-24 | GSE217038 | GEO
Project description:PD-1 blockade therapy, harnessing the cytotoxic potential of CD8+ T cells, has yielded clinical success in treating malignancies. However, its efficacy is often limited due to the progressive differentiation of intratumoral CD8+ T cells into a hypofunctional state known as terminal exhaustion. Despite identifying CD8+ T cell subsets associated with immunotherapy resistance, the molecular pathway triggering the resistance remains elusive. Given the clear association of CD38 with CD8+ T cell subsets resistant to anti-PD1 therapy, we investigated its role in inducing resistance. Phenotypic and functional characterization, along with single-cell RNA sequencing analysis of both in vitro chronically stimulated and intratumoral CD8+ T cells, revealed that CD38-expressing CD8+ T cells are terminally exhausted. Exploring the molecular mechanism, we discovered that CD38 expression was crucial in promoting terminal differentiation of CD8+ T cells by suppressing TCF1 expression, thereby rendering them unresponsive to anti-PD1 therapy. Genetic ablation of CD38 in tumor reactive CD8+ T cells restored TCF1 levels and improved the responsiveness to anti-PD1 therapy in mice. Mechanistically, CD38 expression on exhausted CD8+ T cells elevated intracellular Ca2+ levels through RyR2 calcium channel activation. This, in turn, promoted chronic AKT activation, leading to TCF1 loss. Knockdown of RyR2 or inhibition of AKT in CD8+ T cells maintained TCF1 levels, induced a sustained anti-tumor response, and enhanced responsiveness to anti-PD1 therapy. Thus, targeting CD38 represents a potential strategy to improve the efficacy of anti-PD1 treatment in cancer.
2024-01-12 | GSE251829 | GEO
Project description:Tumor-specific CD8+ T cells are heterogeneous; Tcf1+ stem-like CD8+ T cells give rise to cytotoxic Tim-3+ terminally differentiated CD8+ T cells. The goal of this study is to determine the capacity of CD69 to regulate differentiation of tumor-specific CD8+ T cells in the tumor microenvironment and tumor-draining lymph nodes. Our single-cell RNA-seq and RNA-seq analyses of tumor-specific CD8+ T cells reveal the important function of CD69 in anti-tumor CD8+ T cell immunity. Thus, CD69 is an attractive target for cancer immunotherapy.
2023-03-29 | GSE228386 | GEO